Article
Oncology
Jorge J. Castillo, Kirsten Meid, Joshua N. Gustine, Carly Leventoff, Timothy White, Catherine A. Flynn, Shayna Sarosiek, Maria G. Demos, Maria L. Guerrera, Amanda Kofides, Xia Liu, Manit Munshi, Nicholas Tsakmaklis, Lian Xu, Guang Yang, Andrew R. Branagan, Elizabeth O'Donnell, Noopur Raje, Andrew J. Yee, Christopher J. Patterson, Zachary R. Hunter, Steven P. Treon
Summary: Ibrutinib monotherapy showed durable responses in treatment-naive patients with Waldenstrom macroglobulinemia, with CXCR4 mutations impacting VGPR attainment, time to major response, and 4-year PFS rate.
Article
Oncology
Jorge J. Castillo, John N. Allan, Tanya Siddiqi, Ranjana H. Advani, Kirsten Meid, Carly Leventoff, Timothy P. White, Catherine A. Flynn, Shayna Sarosiek, Andrew R. Branagan, Maria G. Demos, Maria L. Guerrera, Amanda Kofides, Xia Liu, Manit Munshi, Nicholas Tsakmaklis, Lian Xu, Guang Yang, Christopher J. Patterson, Zachary R. Hunter, Matthew S. Davids, Richard R. Furman, Steven P. Treon
Summary: Venetoclax demonstrates safety and efficacy in previously treated WM patients, including those who previously received BTKis. CXCR4 mutation status does not affect treatment response.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Hematology
Joshua N. Gustine, Shayna Sarosiek, Catherine A. Flynn, Kirsten Meid, Carly Leventoff, Timothy White, Maria Luisa Guerrera, Lian Xu, Amanda Kofides, Nicholas Tsakmaklis, Manit Munshi, Maria Demos, Christopher J. Patterson, Xia Liu, Guang Yang, Zachary R. Hunter, Andrew R. Branagan, Steven P. Treon, Jorge J. Castillo
Summary: Continuation of ibrutinib until subsequent treatment is associated with improved disease control and clinical outcomes in patients with acquired resistance to ibrutinib monotherapy for Waldenstrom macroglobulinemia.
Article
Hematology
Steven P. Treon, Kirsten Meid, Zachary R. Hunter, Catherine A. Flynn, Shayna R. Sarosiek, Carly R. Leventoff, Timothy P. White, Yang Cao, Aldo M. Roccaro, Antonio Sacco, Maria G. Demos, Maria Luisa Guerrera, Amanda Kofides, Xia Liu, Lian Xu, Christopher J. Patterson, Manit Munshi, Nicholas Tsakmaklis, Guang Yang, Irene M. Ghobrial, Andrew R. Branagan, Jorge J. Castillo
Summary: The study examined the combination of CXCR4-antagonist ulocuplumab and ibrutinib in treating WM patients, demonstrating promising clinical efficacy and survival outcomes.
Article
Hematology
Cecile Tomowiak, Stephanie Poulain, Charles Herbaux, Aurore Perrot, Beatrice Mahe, Pierre Morel, Therese Aurran, Olivier Tournilhac, Stephane Lepretre, Souad Assaad, Bruno Villemagne, Olivier Casasnovas, Delphine Nollet, Damien Roos-Weil, Sylvie Chevret, Veronique Leblond
Summary: The combination of idelalisib + obinutuzumab was effective in treating R/R WM, with high overall response rate and major response rate. Genetic factors, specifically CXCR4 genotypes, did not significantly impact treatment outcomes, but TP53 mutations were associated with poorer survival. However, some patients discontinued the study due to side effects.
Article
Hematology
Shayna Sarosiek, Joshua N. N. Gustine, Catherine A. A. Flynn, Carly Leventoff, Megan Little, Timothy White, Kirsten Meid, Steven P. P. Treon, Jorge J. J. Castillo
Summary: Waldenstrom macroglobulinaemia (WM) is a type of blood cancer with a specific mutation known as MYD88(L265P). This mutation activates the Bruton tyrosine kinase (BTK), promoting the growth and survival of malignant cells. Ibrutinib is a BTK inhibitor approved for the treatment of WM. However, the impact of reducing the dosage of ibrutinib has not been extensively studied.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Hematology
Jorge J. Castillo, Shayna R. Sarosiek, Joshua N. Gustine, Catherine A. Flynn, Carly R. Leventoff, Timothy P. White, Kirsten Meid, Maria L. Guerrera, Amanda Kofides, Xia Liu, Manit Munshi, Nicholas Tsakmaklis, Zachary R. Hunter, Christopher J. Patterson, Andrew R. Branagan, Steven P. Treon
Summary: This study confirms the predictive and prognostic value of CXCR4 mutations in patients with Waldenstroeurom macroglobulinemia (WM) treated with ibrutinib monotherapy.
Article
Hematology
Maria Poza, Rodrigo Iniguez, Irene Zamanillo, Sara Redondo, Rafael Alonso, Joaquin Martinez-Lopez, Ana Jimenez-Ubieto
Summary: In Waldenstrom macroglobulinemia patients with acquired von Willebrand syndrome, treatment with ibrutinib may lead to a rapid increase in von Willebrand factor levels, improving bleeding symptoms despite only achieving partial response in IgM levels. This improvement could be attributed to reduced glycoprotein Ib receptor expression induced by ibrutinib and subsequent increase in von Willebrand factor levels in the blood.
THERAPEUTIC ADVANCES IN HEMATOLOGY
(2021)
Article
Oncology
Judith Trotman, Christian Buske, Alessandra Tedeschi, Jeffrey V. Matous, David MacDonald, Constantine S. Tam, Olivier Tournilhac, Shuo Ma, Steven P. Treon, Albert Oriol, Jerry Ping, Eva M. Briso, Israel Arango-Hisijara, Meletios A. Dimopoulos
Summary: The study demonstrates that single-agent ibrutinib continues to show sustained efficacy and tolerability in patients with heavily pretreated, rituximab-refractory Waldenstrom macroglobulinemia. The response rates deepened over time during the long-term treatment.
CLINICAL CANCER RESEARCH
(2021)
Article
Orthopedics
Martin Husen, Devin P. Leland, Heath P. Melugin, Keshav Poudel, Mario Hevesi, Bruce A. Levy, Aaron J. Krych
Summary: This study evaluated the long-term outcomes of hip arthroscopy in patients with femoroacetabular impingement (FAI) and compared the results with a nonoperative cohort. The study found a lower rate of osteoarthritis progression in the operative group. Male sex, increased age at initial diagnosis, presence of cam morphology, and increased initial arthritic joint changes were identified as risk factors for failure.
AMERICAN JOURNAL OF SPORTS MEDICINE
(2023)
Article
Oncology
S. Ferrero, Massimo Gentile, Luca Laurenti, Francesca Romana Mauro, Maurizio Martelli, Paolo Sportoletti, Carlo Visco, Pier Luigi Zinzani, Alessandra Tedeschi, M. Varettoni
Summary: A panel of Italian experts convened to provide real world recommendations on the use of BTK inhibitors in lymphoproliferative diseases, particularly in patients with WM. This position paper represents the collective analysis, evaluation, and opinions of the panel, addressing frequently asked questions by clinicians based on currently available evidence.
HEMATOLOGICAL ONCOLOGY
(2022)
Article
Ophthalmology
S. E. Detiger, G. J. Hotte, R. M. Verdijk, R. O. B. de Keizer, P. M. van Hagen, J. A. M. van Laar, D. Paridaens
Summary: This study describes the clinical behavior, treatment effect, and long-term outcome of a series of patients with adult orbital xanthogranulomatous disease (AOXGD). Different subtypes require different treatment options, with surgical excision potentially suitable for AOX patients, while systemic therapy is warranted for AAPOX, NBX, and ECD patients. There is currently no conclusive evidence for a superior treatment strategy and further research is needed.
Article
Sport Sciences
Ori Safran, Shaul Beyth, Charles Milgrom, Yael Milgrom, Dana Nir, Aharon S. Finestone
Summary: This study followed up a cohort of young male traumatic shoulder dislocators for 13 to 17 years. The results showed that those with a positive apprehension test after rehabilitation had a higher risk of recurrence and poorer long-term outcomes. Most subjects still experienced shoulder symptoms at long-term follow-up.
JOURNAL OF SCIENCE AND MEDICINE IN SPORT
(2023)
Article
Oncology
Andreas Hochhaus, Delphine Rea, Carla Boquimpani, Yosuke Minami, Jorge E. Cortes, Timothy P. Hughes, Jane F. Apperley, Elza Lomaia, Sergey Voloshin, Anna Turkina, Dong-Wook Kim, Andre Abdo, Laura Maria Fogliatto, Philipp le Coutre, Koji Sasaki, Dennis Dong Hwan Kim, Susanne Saussele, Mario Annunziata, Naeem Chaudhri, Lynette Chee, Valentin Garcia-Gutierrez, Shruti Kapoor, Alex Allepuz, Sara Quenet, Veronique Bedoucha, Michael J. Mauro
Summary: Asciminib, a BCR-ABL1 inhibitor that targets the ABL Myristoyl Pocket (STAMP), is approved worldwide for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (CML-CP) who have been previously treated with at least 2 tyrosine kinase inhibitors (TKIs). In the ASCEMBL study, asciminib demonstrated superior efficacy and better safety and tolerability compared to bosutinib in patients with CML-CP who had received at least 2 prior TKIs. The major molecular response rate at week 96 was significantly higher with asciminib than with bosutinib, and fewer adverse events and treatment discontinuations were observed with asciminib.
Article
Hematology
Emanuele Cencini, Ilaria Romano, Francesco Ghio, Chiara Camerini, Ilaria Bertaggia, Roberta Giachetti, Lara Mannelli, Maria Teresa Pirrotta, Giulia Lucco Navei, Manuel Ciceri, Giulia Cervetti, Emanuela Sant'Antonio, Federico Simonetti, Silvia Birtolo, Benedetta Puccini, Monica Bocchia, Alberto Fabbri
Summary: This study retrospectively analyzed 49 consecutive R/R WM patients treated with ibrutinib, the overall response rate reached 91.8%. The 2-year progression-free survival rate was 76.7%, and the duration of response was sustained. Treatment toxicity was common but manageable in most cases without discontinuation.
ANNALS OF HEMATOLOGY
(2023)
Review
Hematology
Jorge J. Castillo, Christian Buske, Judith Trotman, Shayna Sarosiek, Steven P. Treon
Summary: BTK inhibitors play a crucial role in the treatment of Waldenstrom macroglobulinemia, being the only FDA-approved agents for these patients. However, there are still unmet needs with BTK inhibitor therapy, such as indefinite duration therapy, high cost, scarcity of complete responses, and lower response rates in patients with CXCR4 mutations. This review focuses on the data supporting the use of covalent BTK inhibitors, management issues, clinical trials with covalent BTK inhibitor combination regimens, and upcoming non-covalent BTK inhibitors.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Review
Hematology
H. Miles Prince, Martin Hutchings, Eva Domingo-Domenech, Dennis A. Eichenauer, Ranjana Advani
Summary: This article summarizes 10 years of experience with brentuximab vedotin for the treatment of CD30-positive lymphomas, discusses the development of novel therapies targeting CD30, and highlights remaining controversies and unanswered questions in CD30-targeted therapy across different lymphoma types. The evidence shows that exploiting CD30 can provide sustained benefits in various CD30-positive lymphomas, and there are promising preliminary results with combination therapy using brentuximab vedotin and immune checkpoint inhibitors.
ANNALS OF HEMATOLOGY
(2023)
Article
Hematology
Shayna Sarosiek, Joshua N. N. Gustine, Catherine A. A. Flynn, Carly Leventoff, Megan Little, Timothy White, Kirsten Meid, Steven P. P. Treon, Jorge J. J. Castillo
Summary: Waldenstrom macroglobulinaemia (WM) is a type of blood cancer with a specific mutation known as MYD88(L265P). This mutation activates the Bruton tyrosine kinase (BTK), promoting the growth and survival of malignant cells. Ibrutinib is a BTK inhibitor approved for the treatment of WM. However, the impact of reducing the dosage of ibrutinib has not been extensively studied.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Denisse Castro, Bryan Valcarcel, Thanya Runciman, Yesenia Huerta-Collado, Sally Paredes, Brady E. Beltran, Jorge J. Castillo, Luis Malpica
Summary: We evaluated the effect of high red distribution width-coefficient of variation (RDW-CV) values (>14%) on all-cause and lymphoma-specific mortality outcomes among 118 patients with peripheral T-cell lymphoma (PTCL). Results showed that patients with a high RDW-CV had a lower overall survival rate and a higher cumulative incidence of lymphoma mortality. RDW-CV emerges as an easily accessible and complementary prognostic biomarker for risk stratification among treated patients with de novo PTCL.
LEUKEMIA & LYMPHOMA
(2023)
Article
Hematology
Steven P. Treona, Alessandra Tedeschi, Jesus San-Miguel, Ramon Garcia-Sanz, Kenneth C. Anderson, Eva Kimby, Monique C. Minnema, Giulia Benevolo, Lugui Qiu, Shuhui Yi, Evangelos Terpos, Constantine S. Tam, Jorge J. Castillo, Pierre Morel, Meletios Dimopoulos, Roger G. Owen
Summary: The consensus panel reviewed the current criteria for diagnosis and response assessment of Waldenstrom's Macroglobulinemia. The key recommendations included reaffirming the previous consensus panel's recommendation to not use arbitrary values for laboratory parameters to distinguish between Waldenstrom's Macroglobulinemia and IgM MGUS, delineating IgM MGUS into two subclasses, and recognizing simplified response assessments using serum IgM levels.
SEMINARS IN HEMATOLOGY
(2023)
Article
Hematology
Christian Buskea, Jorge J. Castillo, Jithma Prasad Abeykoonc, Ranjana Advanid, Suzanne O. Arulogune, Andrew R. Branaganf, Xinxin Caog, Shirley D'Sae, Jian Houh, Prashant Kapoorc, Efstathios Kastritisi, Marie J. Kerstenj, Veronique LeBlondk, Merav Leibal, Jeffrey V. Matous, Jonas Paludo, Lugui Qiu, Constantine S. Tam, Alessandra Tedeschi, Sheeba K. Thomas, Ibrahim Tohidi-Esfahani, Marzia Varettonis, Josephine M. Vosj, Ramon Garcia-Sanz, Jesus San-Miguel, Meletios A. Dimopoulos, Steven P. Treon, Judith Trotmanr
Summary: The consensus panel recommends watchful waiting for asymptomatic patients, and chemoimmunotherapy (CIT) regimens or covalent BTK inhibitors (cBTKi) for first-line treatment of symptomatic patients. The mutational status of MYD88 and CXCR4 should be determined before treatment initiation. Treatment approaches for WM-associated complications aim to reduce tumor burden and abnormal protein levels. Patients' participation in clinical trials is crucial for the continuous improvement of treatment options.
SEMINARS IN HEMATOLOGY
(2023)
Article
Hematology
S. D'Sa, J. Matous, R. Advani, C. Buske, J. J. Castillo, M. Gatt, P. Kapoor, M. J. Kersten, V Leblond, M. Leiba, M. L. Palomba, J. Paludo, L. Qiu, S. Sarosiek, M. Shadman, D. Talaulikar, C. S. Tam, A. Tedeschi, S. K. Thomas, I Tohidi-Esfahani, J. Trotman, M. Varettoni, J. M. Vos, R. Garcia-Sanz, J. San-Miguel, M. A. Dimopoulos, S. P. Treon, E. Kastritis
Summary: The consensus panel 2 (CP2) of the 11th International Workshop on Waldenstrom's macroglobulinemia (IWWM-11) updated the recommendations for treating patients with relapsed or refractory WM (RRWM) based on current data. The key recommendations include considering chemoimmunotherapy and/or covalent Bruton tyrosine kinase strategies, taking into account patient characteristics, disease phenotype, mutational status, and toxicities. After BTKi failure, various treatment options such as different CIT regimens, addition of anti-CD20 antibody, and newer BTKi or non-covalent BTKi can be considered. Participation in clinical trials should be encouraged.
SEMINARS IN HEMATOLOGY
(2023)
Article
Hematology
Greg Hapgood, Monica Civallero, Yana Stepanishyna, Julie Vose, Monica Elena Cabrera, Ranjana H. Advani, Stefano A. Pileri, Martina Manni, Steven M. Horwitz, Francine M. Foss, Felicitas Hitz, John Radford, Ivan Dlouhy, Carlos Chiattone, Won Seog Kim, Tetiana Skrypets, Arnon Nagler, Judith Trotman, Stefano Luminari, Int T Cell Project
Summary: This study investigated the natural history and prognostic factors of limited-stage peripheral T-cell lymphomas (PTCLs) and developed a predictive model for overall survival (OS), which showed good discriminatory power and was validated in an independent cohort.
Letter
Oncology
Shayna Sarosiek, Steven P. Treon, Andrew R. Branagan, Jorge J. Castillo
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Letter
Oncology
Bonnie W. Leung, Christopher J. Fay, Jordan T. Said, Anthony R. Sheets, Christine G. Lian, Jennifer R. Brown, Jorge J. Castillo, Shayna Sarosiek, Catherine Flynn, Nicole R. Leboeuf
LEUKEMIA & LYMPHOMA
(2023)
Meeting Abstract
Oncology
N. J. Park, S. M. Hiniker, H. H. Guo, R. H. Advani, R. T. Hoppe, M. S. Binkley
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)